Skip to main content
Hyper Corporation Inc. logo

Hyper Corporation Inc. — Investor Relations & Filings

Ticker · 065650 ISIN · KR7065650004 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 391 across all filing types
Latest filing 2021-06-21 Capital/Financing Update
Country KR South Korea
Listing KO 065650

About Hyper Corporation Inc.

https://hyper-corp.com/

Hyper Corporation Inc. is a company transitioning from a clinical-stage biopharmaceutical firm to a new-tech-based platform provider. Its core Bio & Healthcare division develops treatments and diagnostic technologies for neurodegenerative diseases like Alzheimer's, aiming to build a comprehensive digital senior healthcare platform. The company is expanding by integrating AI and blockchain technologies into new sectors. Its IP & Content division focuses on securing intellectual property and innovating content distribution, while its New Tech division develops platforms to connect online and offline services. This strategy fuses its biotechnology expertise with advanced IT to create new business models and services.

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시)(부동산투자신탁 수익증권 양수도 계약 체결)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'voluntary disclosure' (자율공시) of a real estate investment trust (REIT) asset acquisition contract. It details the parties involved, the asset, the transaction amount, and the board resolution date. Since it is a specific corporate event disclosure that does not fit into categories like M&A (which usually refers to corporate mergers/takeovers) or other specific financial reports, it falls under the general regulatory filing category.
2021-06-21 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity or individual's shareholding in a listed company crosses certain thresholds (typically 5%). This document details the changes in share ownership, including specific transaction dates, methods (market sales), and the identities of the reporting parties and special relations. It is a standard regulatory disclosure form, not an annual report, earnings release, or proxy statement.
2021-06-08 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification regarding the exercise of conversion rights (전환청구권행사) for convertible bonds into shares. This involves a change in the company's capital structure as new shares are issued upon conversion. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2021-06-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a South Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) when an insider (executive or major shareholder) changes their shareholding position. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2021-05-20 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (acquisitions/disposals) by a major shareholder and their special related parties in the company 'Medifron DBT'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2021-05-17 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Medifron DBT Co., Ltd. for the period of January 1, 2021, to March 31, 2021. It contains detailed company information, financial data, capital changes, and governance details, which are characteristic of an interim/quarterly financial report. It is not a mere announcement or certification, as it provides substantive financial and operational information. Q1 2021
2021-05-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.